Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Ehrlich ascites tumor as a tool in the development of compounds with immunomodulatory properties
Author: Queiroz, MLS
Valadares, MC
Bincoletto, C
Dieamant, GC
Abstract: In previous works, we have demonstrated that the myeloprotective properties of several natural and synthetic compounds are partly responsible for their antitumor activity in the Ehrlich ascites tumor (EAT) model. In this work, we present information that may be useful to the study of pharmacological and toxicological properties of compounds that affect the hematological compartment. Clonogenic studies in EAT-inoculated mice demonstrated a rapid decrease in bone marrow CFU-GM, whereas a progressive increase in splenic CFU-GM and cellularity was observed, followed by splenomegaly. Bone marrow cellularity declined on the third day after tumor challenge, returning to normal values thereafter. Serum from EAT-bearing mice produced detectable colony-stimulating activity in vitro. Similar results were observed with the conditioned medium from Ehrlich tumor cell cultures, but not with the cell-free Ehrlich tumor ascitic fluid. Tumor inoculation also resulted in a more striking depletion in the number of non-adherent cells in long-term bone marrow cell cultures (LTBMCs) with no bone marrow stroma formation. We speculate that the physiological alterations induced by the EAT growth can be used to assess the ability of compounds to modulate the hematopoietic response.
Subject: Ehrlich ascites tumor
development of antitumoral compounds
long-term bone marrow culture
Country: EUA
Editor: Marcel Dekker Inc
Citation: Immunopharmacology And Immunotoxicology. Marcel Dekker Inc, v. 26, n. 4, n. 511, n. 525, 2004.
Rights: fechado
Identifier DOI: 10.1081/IPH-200042289
Date Issue: 2004
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
WOS000226220000003.pdf1.56 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.